Appendix 1: Full Inclusion/Exclusion criteria for PISCES III

Inclusion	Exclusion
1. Written informed consent or witnessed informed consent in the event that the subject is unable to sign informed consent. 2. Ischemic stroke that includes the supratentorial region occurring within 6 to 12 months of the time that surgical intervention will be performed (Qualifying Stroke Event) 3. Aged between 35 and 75 (inclusive) 4. Qualifying Stroke Event must be confirmed by CT or MRI 5. Must have current Moderate or Moderately Severe disability as measured by modified Rankin Score = 3 or 4 due to the Qualifying Stroke Event 6. Must have some residual upper limb movement as defined by the GRASP manual e.g. ability to actively shoulder shrug against gravity and wrist extension (palpable by the investigator; or visible lift of the fingers with hand on table) 7. Must have sufficient cognitive and language abilities to comprehend verbal commands for study assessments 8. No medical conditions that would preclude neurosurgery with appropriate preparation and management. 9. Sufficient putamen, globus pallidus or caudate nucleus volume to enable delivery of the CTX0E03 DP 10. Able to attend study related Visits and complete any diary, telephone or questionnaire assessments 11. Females of childbearing potential (FOCBP), (or within 2 years of last menstrual cycle) must have a confirmed negative pregnancy test at time of treatment and agree to use two r reliable methods of contraception (e.g. oral contraceptive and condom, intra-uterine device and condom, diaphragm with spermicide and condom) for six months following surgery 12. Sexually active males with partners who are FOCBP must be willing to use a reliable method of contraception (e.g. barrier and spermicide or as described above) for six months following surgery.	1. Permanent disability corresponding to a Modified Rankin Score of >1 prior to the Qualifying Stroke Event. 2.Stroke due to hemorrhage or related-to connective tissue disorder, congenital disorder of the cerebral vessels or a disorder of thrombosis Subjects with atrial fibrillation as a suspected cause of stroke are NOT excluded. 3. Neurosurgical pathway obstructed by vascular malformation or cavity 4. History of neurological or other disease resulting in significant functional impairment 5. Any contraindications to either CT scan or MRI 6. Inability to stop or transition off valproic acid or other demethylating agents or HDAC inhibitors for 1 week before and 4 weeks after treatment with CTX0E03 DP 7. Use of selective serotonin reuptake inhibitors (SSRI), unless the subject is on a stable dose that has been started at least 2 months before screening 8. Use of antispasticity medications (excluding oral antispasticity medications if they have been taken regularly for at least four months prior to treatment with CTX0E03) 9. Inability to discontinue anticoagulation therapy 10. Severe comorbid disorder that has reasonable likelihood of limiting survival to less than 24 months. 11. History of malignant disease within the last 5 years, (excluding benign tumors such as non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer) 12. Any history of primary or secondary brain malignant disease. 13. Previous participation in a cell-based therapy study at any time or in any other study involving an investigational product or rehabilitation study within the last 30 days 14. Clinically significant laboratory values, including positive Class I HLA antibodies specific for CTX0E03, during screening 15. Inability to adhere to the study post-surgery upper limb standard PT regimen e.g. excessive spasticity or pain 16. Planned initiation of any other new physical therapy regimen within 6-months post-treatment 17. Any other conditions that, in the opinion of the investigators, would preclude safe or effective participation

CT (computed tomography); CTX0E03 (investigational product); FOCBP (female of child bearing potential); GRASP (graded repetitive arm supplementary program); HDAC (histone deacetylase inhibitor); HLA (human leukocyte antigen); MRI (magnetic resonance imaging); PT (Physical Therapy)